Last reviewed · How we verify
Botox Injectable Product
At a glance
| Generic name | Botox Injectable Product |
|---|---|
| Also known as | Xeomin |
| Sponsor | Federal University of Pelotas |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (PHASE4)
- A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity (PHASE3)
- A Real-World Study on Effect of Hirudoid on Ecchymosis After Treatment of Crow's Feet With Botulinum Toxin Type A (PHASE4)
- Botulinum Toxin Versus Platelet Rich Fibrin for TMJ Internal Derangement (NA)
- A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) (PHASE3)
- Exercise to Improve Sleep and Quality of Life in Stroke Patients Receiving Botulinum Toxin Treatment (NA)
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- OnabotulinumtoxinA for Trigeminal Neuralgia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Botox Injectable Product CI brief — competitive landscape report
- Botox Injectable Product updates RSS · CI watch RSS
- Federal University of Pelotas portfolio CI